Who owns Entrada Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of TRDA from SEC Form 13F filings across 128 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 128 institutions disclosed 29.1M shares of Entrada Therapeutics, Inc. worth $214.4M — about 68.9% of shares outstanding; the largest disclosed holder is BAKER BROS. ADVISORS LP. Source: SEC Form 13F filings, parsed by EvidInvest.
128
13F holders
$214.4M
value, 2026 filers
68.9%
of shares outstanding (29.1M sh)
26
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of TRDA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 5.1M | $37.3M | 0.2% | 12% | 0.0% |
| 2 | 5AM Venture Management, LLC | 4.1M | $29.9M | 10.4% | 9.6% | 0.0% |
| 3 | BlackRock, Inc. | 2.6M | $19.0M | 0.0% | 6.1% | +9.5% |
| 4 | Merck & Co., Inc.NEW | 1.7M | $12.8M | 2.4% | 4.1% | new |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $9.3M | 0.0% | 3% | +1.1% |
| 6 | MPM BIOIMPACT LLCNEW | 1.3M | $9.2M | 0.6% | 3% | new |
| 7 | TCG Crossover Management, LLC | 1.1M | $7.8M | 0.2% | 2.5% | -53.7% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 954,419 | $7.0M | 0.0% | 2.3% | -7.8% |
| 9 | MILLENNIUM MANAGEMENT LLC | 763,959 | $5.6M | 0.0% | 1.8% | +47.1% |
| 10 | StepStone Group LP | 761,277 | $5.6M | 0.3% | 1.8% | 0.0% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 717,430 | $5.3M | 0.0% | 1.7% | +7.5% |
| 12 | AQR CAPITAL MANAGEMENT LLC | 699,537 | $5.1M | 0.0% | 1.7% | +780.0% |
| 13 | STATE STREET CORP | 596,677 | $4.4M | 0.0% | 1.4% | +11.8% |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 542,316 | $4.0M | 0.0% | 1.3% | +3.1% |
| 15 | JPMORGAN CHASE & CO | 496,457 | $3.8M | 0.0% | 1.2% | +3243.8% |
| 16 | ACADIAN ASSET MANAGEMENT LLC | 400,862 | $2.9M | 0.0% | 0.9% | +20.3% |
| 17 | CITADEL ADVISORS LLC | 394,323 | $2.9M | 0.0% | 0.9% | +83.4% |
| 18 | DIMENSIONAL FUND ADVISORS LP | 376,136 | $2.8M | 0.0% | 0.9% | +15.9% |
| 19 | NORTHERN TRUST CORP | 309,942 | $2.3M | 0.0% | 0.7% | +31.9% |
| 20 | JACOBS LEVY EQUITY MANAGEMENT, INC | 303,459 | $2.2M | 0.0% | 0.7% | -9.1% |
| 21 | Nantahala Capital Management, LLC | 300,575 | $2.2M | 0.1% | 0.7% | +88.6% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 254,130 | $1.9M | 0.0% | 0.6% | +15.3% |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 197,136 | $1.5M | 0.0% | 0.5% | -8.2% |
| 24 | Longaeva Partners L.P. | 195,237 | $1.4M | 0.0% | 0.5% | -4.8% |
| 25 | MORGAN STANLEY | 191,650 | $1.4M | 0.0% | 0.5% | +8.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.